Supplementary Figures S1-6 from Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer

Supplementary Figure S1. RNAi screen to identify kinases that sensitize cells to CDK4/6 inhibition. Supplementary Figure S2. Calculation of the sensitivity index (SI) value. Supplementary Figure S3. PDK1 and CDK4/6 inhibitors are synergistic against a panel of cancer cell lines. Supplementary Figure S4. Inhibition of the PI3K/PDK1 pathway results in durable responses and is well-tolerated in vivo. Supplementary Figure S5. Ribociclib-resistant cells are cross-resistant to other CDK4/6 inhibitors and upregulate P-PDK1. Supplementary Figure S6. Inhibition of PI3K/PDK1/AKT/mTOR signaling pathway resensitizes ribociclib-resistant cells to CDK4/6 inhibition.